Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145298 · ClinicalTrials.gov registry record · Phase 1
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
A Phase 1 study of Pulmonary Arterial Hypertension PAH, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03145298 is a Phase 1 study of Pulmonary Arterial Hypertension PAH that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 26 participants, below the 43-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03145298, a Phase 1 study of Pulmonary Arterial Hypertension PAH, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration of allogeneic CDCs have the potential to reduce adverse arteriolar remodeling in PAH which was the basis for the approved investigational new drug (IND). The use of CDCs as an adjunctive therapy in patients comprising 4 sub-groups of patients with PAH in which inflammation and immune dysfunction are key pathophysiologic drivers of PAH.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Allogeneic Human Cardiosphere-Derived Stem Cells
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03145298
The ClinicalTrials.gov registry entry for NCT03145298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (40% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03145298 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03145298 about?
NCT03145298 is a clinical study titled "ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy". Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration o...
What is the current status of trial NCT03145298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-10-01. Estimated completion is 2023-03-31.
What conditions does trial NCT03145298 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH.
What interventions are being tested in trial NCT03145298?
The interventions under investigation include: Placebo (BIOLOGICAL), Allogeneic Human Cardiosphere-Derived Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03145298?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03145298 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension PAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Intravenous ZMA001 in Healthy Subjects
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
RECRUITING · NA
-
PAH Exercise Study
RECRUITING · Phase 3
-
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.